Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatment

Fig. 1

a Cluster analysis of NYHA heart failure classification. b Cluster analysis of CCS grading of angina pectoris scores before and after approximately 10 years of agalsidase alfa enzyme replacement therapy. Values in the boxes indicate the numbers (and percentages) of patients in that category. Arrows indicate directions of changes in classifications or scores, and numbers adjacent to arrows show the number of patients with that change. CCS: Canadian Cardiovascular Society; NYHA: New York Heart Association

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172